Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3 | Future Oncology
Overall survival LUX-Lung 3 and LUX-Lung 6 (patients with Del19 and... | Download Scientific Diagram
Patients with Brain Metastases | Afatinib NSCLC Trials | InOncology
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX- Lung 7 trial - Annals of Oncology
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chin | OTT
Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer - Cancer Treatment Reviews
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial - Annals of Oncology
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 - The Lancet Oncology
LUX-Lung 7 slide kit
EGFR-mutation-positive NSCLC: expanding the data pool for established treatment options - memoinOncology
InOncology | LUX-Lung 3 Clinical Trial | Afatinib NSCLC Trials & Studies | Boehringer Ingelheim
Moving Care Forward in Advanced NSCLC: Optimizing Multidisciplinary Management (Transcript)
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study - Lung
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials - The Lancet Oncology
Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients - ESMO Open
Patients with Brain Metastases | Afatinib NSCLC Trials | InOncology
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 | British Journal of Cancer
researchopenworld.com
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer - Journal of Thoracic
LUX Lung 3 Clinical Trial Infographic (Boehringer Ingelheim) | Clinical trials, Boehringer ingelheim, Trials
LUX-Lung 8 A randomised, open-label phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line. - ppt download
Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations - Clinical Lung Cancer
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial - The Lancet Oncology
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives | Oncotarget
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases - Journal of Thoracic Oncology
LUX-Lung 8 A randomised, open-label phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line. - ppt download
